_id
69130873ccc777a4e85d7b59
Ticker
JWCTF
Name
JW (Cayman) Therapeutics Co. Ltd
Exchange
PINK
Address
Building B, Shanghai, China
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://www.jwtherapeutics.com
Description
JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacture, and marketing of cellular immunotherapy products in the People's Republic of China. The company offers cell-based immunotherapies, including CAR-T treatment, a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an autologous anti-CD19 chimeric antigen receptor T-cell (CAR-T) immunotherapy for use in the treatment of a range of hematological cancers, as well as systemic lupus erythematosus (SLE), a chronic autoimmune disease. The company's products pipeline includes JWCAR129, a chimeric antigen receptor (CAR) construct therapy for use in the treatment of multiple myeloma; and JWCAR201, a dual targeting autologous CAR T-cell therapy for use in the treatment of B-cell malignancies and autoimmune diseases. It is also developing JWATM204 and JWATM214 for treating hepatocellular carcinoma (HCC); JWATM203 for the treatment of hepatoblastoma (HB) and hepatocellular carcinoma (HCC) in pediatric patients; JWATM213 for treating HCC; JWTCR001 for the treatment of various solid tumors; and JWCAR031 for the treatment of small cell lung cancer. In addition, the company engages in the drug research and development; medical research and experimental development; import and export handling; and clinical trial and CRO, as well as investment holding activities. JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, China.
Last Close
0.36
Volume
-
Current Price
0.36
Change
0
Last Updated
2026-01-04T15:51:35.179Z
Image
-
Ipo Date
-
Market Cap
218315936
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Current Quarter
2025-06-30
Revenue
106346000
Cost Of Revenue
41229000
Gross Profit
65117000
Operating Expenses
182725000
Operating Income
-117608000
Interest Expense
-
Pretax Income
-267265000
Net Income
-267265000
Eps
-0.6430327789968049
Dividends Per Share
-
Shares Outstanding
416232634
Income Tax Expense
-
EBITDA
-80066500
Operating Margin
-110.5899610704681
Total Other Income Expense Net
-149657000
Cash
646880000
Short Term Investments
-
Receivables
25055000
Inventories
67021000
Total Current Assets
747045000
Property Plant Equipment
240272000
Total Assets
1419441000
Payables
79113000
Short Term Debt
331976000
Long Term Debt
19300000
Total Liabilities
510833000
Equity
908608000
Bs_currency_symbol
CNY
Depreciation
33973500
Change In Working Capital
-
Cash From Operations
-
Capital Expenditures
0
Cash From Investing
-
Cash From Financing
-
Net Change In Cash
-
Cf_currency_symbol
-
PE
-
PB
0.16467774882017325
ROE
-29.414775128548285
ROA
-18.82889109163396
FCF
-
Fcf Percent
-
Piotroski FScore
0
Health Score
37
Deep Value Investing Score
6
Defensive Investing Score
6.5
Dividend Investing Score
1.5
Economic Moat Investing Score
3.3
Garp Investing Score
4
Growth Investing Score
3
Momentum Investing Score
2
Net Net Investing Score
4.5
Quality Investing Score
2
Value Investing Score
4.5
Quarters > 0 > quarter
2025-06-30
Quarters > 0 > income Statement > revenue
106346000
Quarters > 0 > income Statement > cost Of Revenue
41229000
Quarters > 0 > income Statement > gross Profit
65117000
Quarters > 0 > income Statement > operating Expenses
182725000
Quarters > 0 > income Statement > operating Income
-117608000
Quarters > 0 > income Statement > interest Expense
-
Quarters > 0 > income Statement > pretax Income
-267265000
Quarters > 0 > income Statement > net Income
-267265000
Quarters > 0 > income Statement > eps
-0.6430327789968049
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
415632000
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-80066500
Quarters > 0 > income Statement > operating Margin
-110.5899610704681
Quarters > 0 > income Statement > total Other Income Expense Net
-149657000
Quarters > 0 > income Statement > currency_symbol
-
Quarters > 0 > balance Sheet > cash
646880000
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
25055000
Quarters > 0 > balance Sheet > inventories
67021000
Quarters > 0 > balance Sheet > total Current Assets
747045000
Quarters > 0 > balance Sheet > property Plant Equipment
240272000
Quarters > 0 > balance Sheet > total Assets
1419441000
Quarters > 0 > balance Sheet > payables
79113000
Quarters > 0 > balance Sheet > short Term Debt
331976000
Quarters > 0 > balance Sheet > long Term Debt
19300000
Quarters > 0 > balance Sheet > total Liabilities
510833000
Quarters > 0 > balance Sheet > equity
908608000
Quarters > 0 > balance Sheet > currency_symbol
CNY
Quarters > 0 > cash Flow > net Income
-267265000
Quarters > 0 > cash Flow > depreciation
33973500
Quarters > 0 > cash Flow > change In Working Capital
-
Quarters > 0 > cash Flow > cash From Operations
-
Quarters > 0 > cash Flow > capital Expenditures
0
Quarters > 0 > cash Flow > cash From Investing
-
Quarters > 0 > cash Flow > cash From Financing
-
Quarters > 0 > cash Flow > net Change In Cash
-
Quarters > 0 > cash Flow > currency_symbol
-
Quarters > 0 > ratios > PE
-0.6430327789968049
Quarters > 0 > ratios > PB
0.16467774882017325
Quarters > 0 > ratios > ROE
-29.414775128548285
Quarters > 0 > ratios > ROA
-18.82889109163396
Quarters > 0 > ratios > FCF
-
Quarters > 0 > ratios > Piotroski FScore
0
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
37
Quarters > 1 > quarter
2025-03-31
Quarters > 1 > income Statement > revenue
53173000
Quarters > 1 > income Statement > cost Of Revenue
20614500
Quarters > 1 > income Statement > gross Profit
32558500
Quarters > 1 > income Statement > operating Expenses
91362500
Quarters > 1 > income Statement > operating Income
-58804000
Quarters > 1 > income Statement > interest Expense
-
Quarters > 1 > income Statement > pretax Income
-133632500
Quarters > 1 > income Statement > net Income
-133632500
Quarters > 1 > income Statement > eps
-0.32151638949840244
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
415632000
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-40033250
Quarters > 1 > income Statement > operating Margin
-110.5899610704681
Quarters > 1 > income Statement > total Other Income Expense Net
-74828500
Quarters > 1 > income Statement > currency_symbol
-
Quarters > 1 > balance Sheet > cash
646880000
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
25055000
Quarters > 1 > balance Sheet > inventories
67021000
Quarters > 1 > balance Sheet > total Current Assets
747045000
Quarters > 1 > balance Sheet > property Plant Equipment
240272000
Quarters > 1 > balance Sheet > total Assets
1419441000
Quarters > 1 > balance Sheet > payables
79113000
Quarters > 1 > balance Sheet > short Term Debt
331976000
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
510833000
Quarters > 1 > balance Sheet > equity
908608000
Quarters > 1 > balance Sheet > currency_symbol
-
Quarters > 1 > cash Flow > net Income
-133632500
Quarters > 1 > cash Flow > depreciation
16986750
Quarters > 1 > cash Flow > change In Working Capital
-
Quarters > 1 > cash Flow > cash From Operations
-
Quarters > 1 > cash Flow > capital Expenditures
0
Quarters > 1 > cash Flow > cash From Investing
-
Quarters > 1 > cash Flow > cash From Financing
-
Quarters > 1 > cash Flow > net Change In Cash
-
Quarters > 1 > cash Flow > currency_symbol
-
Quarters > 1 > ratios > PE
-0.32151638949840244
Quarters > 1 > ratios > PB
0.16467774882017325
Quarters > 1 > ratios > ROE
-14.707387564274143
Quarters > 1 > ratios > ROA
-9.41444554581698
Quarters > 1 > ratios > FCF
-
Quarters > 1 > ratios > Piotroski FScore
0
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
37
Quarters > 2 > quarter
2024-12-31
Quarters > 2 > income Statement > revenue
71403000
Quarters > 2 > income Statement > cost Of Revenue
37832000
Quarters > 2 > income Statement > gross Profit
33571000
Quarters > 2 > income Statement > operating Expenses
-213942000
Quarters > 2 > income Statement > operating Income
247513000
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
-350357000
Quarters > 2 > income Statement > net Income
-350357000
Quarters > 2 > income Statement > eps
-0.8458949503241305
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
414185000
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
-186164000
Quarters > 2 > income Statement > operating Margin
346.64229794266345
Quarters > 2 > income Statement > total Other Income Expense Net
-597870000
Quarters > 2 > income Statement > currency_symbol
-
Quarters > 2 > balance Sheet > cash
757375000
Quarters > 2 > balance Sheet > short Term Investments
5157000
Quarters > 2 > balance Sheet > receivables
-
Quarters > 2 > balance Sheet > inventories
31257000
Quarters > 2 > balance Sheet > total Current Assets
808673000
Quarters > 2 > balance Sheet > property Plant Equipment
275527000
Quarters > 2 > balance Sheet > total Assets
1680364000
Quarters > 2 > balance Sheet > payables
2116000
Quarters > 2 > balance Sheet > short Term Debt
376259000
Quarters > 2 > balance Sheet > long Term Debt
19500000
Quarters > 2 > balance Sheet > total Liabilities
511199000
Quarters > 2 > balance Sheet > equity
1169165000
Quarters > 2 > balance Sheet > currency_symbol
CNY
Quarters > 2 > cash Flow > net Income
-350357000
Quarters > 2 > cash Flow > depreciation
42774000
Quarters > 2 > cash Flow > change In Working Capital
-15597000
Quarters > 2 > cash Flow > cash From Operations
-145239000
Quarters > 2 > cash Flow > capital Expenditures
2353000
Quarters > 2 > cash Flow > cash From Investing
-2481000
Quarters > 2 > cash Flow > cash From Financing
33438000
Quarters > 2 > cash Flow > net Change In Cash
-
Quarters > 2 > cash Flow > currency_symbol
-
Quarters > 2 > ratios > PE
-0.8458949503241305
Quarters > 2 > ratios > PB
0.12753255528518215
Quarters > 2 > ratios > ROE
-29.96642903268572
Quarters > 2 > ratios > ROA
-20.850065819072533
Quarters > 2 > ratios > FCF
-147592000
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-2.067027996022576
Quarters > 2 > health Score
34
Quarters > 3 > quarter
2024-09-30
Quarters > 3 > income Statement > revenue
35701500
Quarters > 3 > income Statement > cost Of Revenue
18916000
Quarters > 3 > income Statement > gross Profit
16785500
Quarters > 3 > income Statement > operating Expenses
-106971000
Quarters > 3 > income Statement > operating Income
123756500
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-175178500
Quarters > 3 > income Statement > net Income
-175178500
Quarters > 3 > income Statement > eps
-0.42294747516206527
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
414185000
Quarters > 3 > income Statement > income Tax Expense
-
Quarters > 3 > income Statement > EBITDA
-93082000
Quarters > 3 > income Statement > operating Margin
346.64229794266345
Quarters > 3 > income Statement > total Other Income Expense Net
-298935000
Quarters > 3 > income Statement > currency_symbol
-
Quarters > 3 > balance Sheet > cash
757375000
Quarters > 3 > balance Sheet > short Term Investments
5157000
Quarters > 3 > balance Sheet > receivables
-
Quarters > 3 > balance Sheet > inventories
31257000
Quarters > 3 > balance Sheet > total Current Assets
808673000
Quarters > 3 > balance Sheet > property Plant Equipment
273880000
Quarters > 3 > balance Sheet > total Assets
1680364000
Quarters > 3 > balance Sheet > payables
40145000
Quarters > 3 > balance Sheet > short Term Debt
376259000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
511199000
Quarters > 3 > balance Sheet > equity
1169165000
Quarters > 3 > balance Sheet > currency_symbol
-
Quarters > 3 > cash Flow > net Income
-175178500
Quarters > 3 > cash Flow > depreciation
21387000
Quarters > 3 > cash Flow > change In Working Capital
-7798500
Quarters > 3 > cash Flow > cash From Operations
-72619500
Quarters > 3 > cash Flow > capital Expenditures
1176500
Quarters > 3 > cash Flow > cash From Investing
-1240500
Quarters > 3 > cash Flow > cash From Financing
16719000
Quarters > 3 > cash Flow > net Change In Cash
-
Quarters > 3 > cash Flow > currency_symbol
-
Quarters > 3 > ratios > PE
-0.42294747516206527
Quarters > 3 > ratios > PB
0.12753255528518215
Quarters > 3 > ratios > ROE
-14.98321451634286
Quarters > 3 > ratios > ROA
-10.425032909536267
Quarters > 3 > ratios > FCF
-73796000
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-2.067027996022576
Quarters > 3 > health Score
34
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
158218000
Annuals > 0 > income Statement > cost Of Revenue
80902000
Annuals > 0 > income Statement > gross Profit
77316000
Annuals > 0 > income Statement > operating Expenses
536597000
Annuals > 0 > income Statement > operating Income
-459281000
Annuals > 0 > income Statement > interest Expense
12220000
Annuals > 0 > income Statement > pretax Income
-590624000
Annuals > 0 > income Statement > net Income
-590624000
Annuals > 0 > income Statement > eps
-1.4278903571756674
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
413634000
Annuals > 0 > income Statement > income Tax Expense
-
Annuals > 0 > income Statement > EBITDA
-488741000
Annuals > 0 > income Statement > operating Margin
-290.28365925495206
Annuals > 0 > income Statement > total Other Income Expense Net
-131343000
Annuals > 0 > income Statement > currency_symbol
USD
Annuals > 0 > balance Sheet > cash
757375000
Annuals > 0 > balance Sheet > short Term Investments
5157000
Annuals > 0 > balance Sheet > receivables
-
Annuals > 0 > balance Sheet > inventories
31257000
Annuals > 0 > balance Sheet > total Current Assets
808673000
Annuals > 0 > balance Sheet > property Plant Equipment
275527000
Annuals > 0 > balance Sheet > total Assets
1680364000
Annuals > 0 > balance Sheet > payables
2116000
Annuals > 0 > balance Sheet > short Term Debt
376259000
Annuals > 0 > balance Sheet > long Term Debt
19500000
Annuals > 0 > balance Sheet > total Liabilities
511199000
Annuals > 0 > balance Sheet > equity
1169165000
Annuals > 0 > balance Sheet > currency_symbol
CNY
Annuals > 0 > cash Flow > net Income
-590624000
Annuals > 0 > cash Flow > depreciation
89663000
Annuals > 0 > cash Flow > change In Working Capital
-29814000
Annuals > 0 > cash Flow > cash From Operations
-333443000
Annuals > 0 > cash Flow > capital Expenditures
15425000
Annuals > 0 > cash Flow > cash From Investing
-15425000
Annuals > 0 > cash Flow > cash From Financing
90490000
Annuals > 0 > cash Flow > net Change In Cash
-248534000
Annuals > 0 > cash Flow > currency_symbol
CNY
Annuals > 0 > ratios > PE
-1.4278903571756674
Annuals > 0 > ratios > PB
0.12736289574183285
Annuals > 0 > ratios > ROE
-50.516736303259165
Annuals > 0 > ratios > ROA
-35.148574951617626
Annuals > 0 > ratios > FCF
-348868000
Annuals > 0 > ratios > Piotroski FScore
0
Annuals > 0 > ratios > fcf Percent
-2.2049829981418045
Annuals > 0 > health Score
33
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
173856000
Annuals > 1 > income Statement > cost Of Revenue
85637000
Annuals > 1 > income Statement > gross Profit
88219000
Annuals > 1 > income Statement > operating Expenses
877826000
Annuals > 1 > income Statement > operating Income
-789607000
Annuals > 1 > income Statement > interest Expense
12415000
Annuals > 1 > income Statement > pretax Income
-767996000
Annuals > 1 > income Statement > net Income
-767996000
Annuals > 1 > income Statement > eps
-1.8661968750759361
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
411530000
Annuals > 1 > income Statement > income Tax Expense
-3298000
Annuals > 1 > income Statement > EBITDA
-655747000
Annuals > 1 > income Statement > operating Margin
-454.1729937419474
Annuals > 1 > income Statement > total Other Income Expense Net
21611000
Annuals > 1 > income Statement > currency_symbol
CNY
Annuals > 1 > balance Sheet > cash
1005909000
Annuals > 1 > balance Sheet > short Term Investments
5534000
Annuals > 1 > balance Sheet > receivables
22791000
Annuals > 1 > balance Sheet > inventories
34778000
Annuals > 1 > balance Sheet > total Current Assets
1067484000
Annuals > 1 > balance Sheet > property Plant Equipment
341131000
Annuals > 1 > balance Sheet > total Assets
2146097000
Annuals > 1 > balance Sheet > payables
3269000
Annuals > 1 > balance Sheet > short Term Debt
121005000
Annuals > 1 > balance Sheet > long Term Debt
157500000
Annuals > 1 > balance Sheet > total Liabilities
462259000
Annuals > 1 > balance Sheet > equity
1683838000
Annuals > 1 > balance Sheet > currency_symbol
CNY
Annuals > 1 > cash Flow > net Income
-767996000
Annuals > 1 > cash Flow > depreciation
99834000
Annuals > 1 > cash Flow > change In Working Capital
3188000
Annuals > 1 > cash Flow > cash From Operations
-398418000
Annuals > 1 > cash Flow > capital Expenditures
14580000
Annuals > 1 > cash Flow > cash From Investing
9904000
Annuals > 1 > cash Flow > cash From Financing
275000
Annuals > 1 > cash Flow > net Change In Cash
-377427000
Annuals > 1 > cash Flow > currency_symbol
CNY
Annuals > 1 > ratios > PE
-1.8661968750759361
Annuals > 1 > ratios > PB
0.08798399846065952
Annuals > 1 > ratios > ROE
-45.60985082888021
Annuals > 1 > ratios > ROA
-35.78570772896099
Annuals > 1 > ratios > FCF
-412998000
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-2.375517669795693
Annuals > 1 > health Score
33
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
145702000
Annuals > 2 > income Statement > cost Of Revenue
86946000
Annuals > 2 > income Statement > gross Profit
58756000
Annuals > 2 > income Statement > operating Expenses
914639000
Annuals > 2 > income Statement > operating Income
-855883000
Annuals > 2 > income Statement > interest Expense
6787000
Annuals > 2 > income Statement > pretax Income
-846135000
Annuals > 2 > income Statement > net Income
-846135000
Annuals > 2 > income Statement > eps
-2.0632758910783653
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
410093000
Annuals > 2 > income Statement > income Tax Expense
67419515
Annuals > 2 > income Statement > EBITDA
-752274000
Annuals > 2 > income Statement > operating Margin
-587.4202138611687
Annuals > 2 > income Statement > total Other Income Expense Net
9748000
Annuals > 2 > income Statement > currency_symbol
CNY
Annuals > 2 > balance Sheet > cash
1383336000
Annuals > 2 > balance Sheet > short Term Investments
5544000
Annuals > 2 > balance Sheet > receivables
5305000
Annuals > 2 > balance Sheet > inventories
40159000
Annuals > 2 > balance Sheet > total Current Assets
1485168000
Annuals > 2 > balance Sheet > property Plant Equipment
393219000
Annuals > 2 > balance Sheet > total Assets
2791347000
Annuals > 2 > balance Sheet > payables
7604000
Annuals > 2 > balance Sheet > short Term Debt
152900000
Annuals > 2 > balance Sheet > long Term Debt
92500000
Annuals > 2 > balance Sheet > total Liabilities
437063000
Annuals > 2 > balance Sheet > equity
2354284000
Annuals > 2 > balance Sheet > currency_symbol
CNY
Annuals > 2 > cash Flow > net Income
-846135000
Annuals > 2 > cash Flow > depreciation
81366000
Annuals > 2 > cash Flow > change In Working Capital
-14062000
Annuals > 2 > cash Flow > cash From Operations
-536722000
Annuals > 2 > cash Flow > capital Expenditures
76874000
Annuals > 2 > cash Flow > cash From Investing
-124083000
Annuals > 2 > cash Flow > cash From Financing
112354000
Annuals > 2 > cash Flow > net Change In Cash
-451063000
Annuals > 2 > cash Flow > currency_symbol
CNY
Annuals > 2 > ratios > PE
-2.0632758910783653
Annuals > 2 > ratios > PB
0.06270844129255435
Annuals > 2 > ratios > ROE
-35.940226412786224
Annuals > 2 > ratios > ROA
-30.31278447287277
Annuals > 2 > ratios > FCF
-613596000
Annuals > 2 > ratios > Piotroski FScore
0
Annuals > 2 > ratios > fcf Percent
-4.21130801224417
Annuals > 2 > health Score
33
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
30797000
Annuals > 3 > income Statement > cost Of Revenue
21752000
Annuals > 3 > income Statement > gross Profit
9045000
Annuals > 3 > income Statement > operating Expenses
768128000
Annuals > 3 > income Statement > operating Income
-759083000
Annuals > 3 > income Statement > interest Expense
2692000
Annuals > 3 > income Statement > pretax Income
-702328000
Annuals > 3 > income Statement > net Income
-702328000
Annuals > 3 > income Statement > eps
-1.756922468849203
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
399749000
Annuals > 3 > income Statement > income Tax Expense
32776442
Annuals > 3 > income Statement > EBITDA
-738703000
Annuals > 3 > income Statement > operating Margin
-2464.795272266779
Annuals > 3 > income Statement > total Other Income Expense Net
56755000
Annuals > 3 > income Statement > currency_symbol
CNY
Annuals > 3 > balance Sheet > cash
1834399000
Annuals > 3 > balance Sheet > short Term Investments
695000
Annuals > 3 > balance Sheet > receivables
2860000
Annuals > 3 > balance Sheet > inventories
31402000
Annuals > 3 > balance Sheet > total Current Assets
1895040000
Annuals > 3 > balance Sheet > property Plant Equipment
380970000
Annuals > 3 > balance Sheet > total Assets
3116606000
Annuals > 3 > balance Sheet > payables
2565000
Annuals > 3 > balance Sheet > short Term Debt
20186000
Annuals > 3 > balance Sheet > long Term Debt
95000000
Annuals > 3 > balance Sheet > total Liabilities
325749000
Annuals > 3 > balance Sheet > equity
2790857000
Annuals > 3 > balance Sheet > currency_symbol
CNY
Annuals > 3 > cash Flow > net Income
-702328000
Annuals > 3 > cash Flow > depreciation
46327000
Annuals > 3 > cash Flow > change In Working Capital
49785000
Annuals > 3 > cash Flow > cash From Operations
-561198000
Annuals > 3 > cash Flow > capital Expenditures
73087000
Annuals > 3 > cash Flow > cash From Investing
-137130000
Annuals > 3 > cash Flow > cash From Financing
-30621000
Annuals > 3 > cash Flow > net Change In Cash
-796199000
Annuals > 3 > cash Flow > currency_symbol
CNY
Annuals > 3 > ratios > PE
-1.756922468849203
Annuals > 3 > ratios > PB
0.051564677086643994
Annuals > 3 > ratios > ROE
-25.16531660346625
Annuals > 3 > ratios > ROA
-22.535026885015302
Annuals > 3 > ratios > FCF
-634285000
Annuals > 3 > ratios > Piotroski FScore
0
Annuals > 3 > ratios > fcf Percent
-20.595674903399683
Annuals > 3 > health Score
33
Valuation > metrics > PE
-0.6430327789968049
Valuation > metrics > PB
0.16467774882017325
Valuation > final Score
70
Valuation > verdict
83.5% Undervalued
Profitability > metrics > ROE
-29.414775128548285
Profitability > metrics > ROA
-35.77629192351197
Profitability > metrics > Net Margin
-2.51316457600662
Profitability > final Score
0
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.5622149485806861
Risk > metrics > Interest Coverage
-0.6282528973255662
Risk > final Score
45
Risk > verdict
High
Liquidity > metrics > Current Ratio
1.8172342242190864
Liquidity > metrics > Quick Ratio
1.6542014016429532
Liquidity > final Score
95
Liquidity > verdict
Great
Prev Valuations > 0
70
Prev Valuations > 1
70
Prev Valuations > 2
70
Prev Profitabilities > 0
0
Prev Profitabilities > 1
0
Prev Profitabilities > 2
0
Prev Risks > 0
45
Prev Risks > 1
66
Prev Risks > 2
66
Prev Liquidities > 0
95
Prev Liquidities > 1
100
Prev Liquidities > 2
99
Updated At
2026-01-20T22:04:50.408Z
Earnings History > 0 > period
2025-12-31
Earnings History > 0 > report Date
2026-03-27
Earnings History > 0 > date
2025-12-31
Earnings History > 0 > before After Market
BeforeMarket
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-
Earnings History > 0 > eps Estimate
-
Earnings History > 0 > eps Difference
0
Earnings History > 0 > surprise Percent
-
Earnings History > 1 > period
2021-03-31
Earnings History > 1 > report Date
2021-06-30
Earnings History > 1 > date
2021-03-31
Earnings History > 1 > before After Market
-
Earnings History > 1 > currency
CNY
Earnings History > 1 > eps Actual
-0.055
Earnings History > 1 > eps Estimate
0
Earnings History > 1 > eps Difference
-0.055
Earnings History > 1 > surprise Percent
-
Earnings History > 2 > period
2020-12-31
Earnings History > 2 > report Date
2021-03-31
Earnings History > 2 > date
2020-12-31
Earnings History > 2 > before After Market
-
Earnings History > 2 > currency
CNY
Earnings History > 2 > eps Actual
-0.0542
Earnings History > 2 > eps Estimate
0
Earnings History > 2 > eps Difference
-0.0542
Earnings History > 2 > surprise Percent
-
Earnings History > 3 > period
2020-09-30
Earnings History > 3 > report Date
2020-12-31
Earnings History > 3 > date
2020-09-30
Earnings History > 3 > before After Market
-
Earnings History > 3 > currency
CNY
Earnings History > 3 > eps Actual
-0.3911
Earnings History > 3 > eps Estimate
0
Earnings History > 3 > eps Difference
-0.3911
Earnings History > 3 > surprise Percent
-
Earnings History > 4 > period
2020-06-30
Earnings History > 4 > report Date
2020-09-30
Earnings History > 4 > date
2020-06-30
Earnings History > 4 > before After Market
-
Earnings History > 4 > currency
CNY
Earnings History > 4 > eps Actual
-0.376
Earnings History > 4 > eps Estimate
0
Earnings History > 4 > eps Difference
-0.376
Earnings History > 4 > surprise Percent
-
Earnings History > 5 > period
2020-03-31
Earnings History > 5 > report Date
2020-06-30
Earnings History > 5 > date
2020-03-31
Earnings History > 5 > before After Market
-
Earnings History > 5 > currency
CNY
Earnings History > 5 > eps Actual
-0.7049
Earnings History > 5 > eps Estimate
0
Earnings History > 5 > eps Difference
-0.7049
Earnings History > 5 > surprise Percent
-
Earnings History > 6 > period
2019-12-31
Earnings History > 6 > report Date
2020-03-31
Earnings History > 6 > date
2019-12-31
Earnings History > 6 > before After Market
-
Earnings History > 6 > currency
CNY
Earnings History > 6 > eps Actual
-0.7032
Earnings History > 6 > eps Estimate
0
Earnings History > 6 > eps Difference
-0.7032
Earnings History > 6 > surprise Percent
-
Earnings History > 7 > period
2019-09-30
Earnings History > 7 > report Date
2019-12-31
Earnings History > 7 > date
2019-09-30
Earnings History > 7 > before After Market
-
Earnings History > 7 > currency
CNY
Earnings History > 7 > eps Actual
-0.3042
Earnings History > 7 > eps Estimate
0
Earnings History > 7 > eps Difference
-0.3042
Earnings History > 7 > surprise Percent
-
Earnings History > 8 > period
2019-06-30
Earnings History > 8 > report Date
2019-09-30
Earnings History > 8 > date
2019-06-30
Earnings History > 8 > before After Market
-
Earnings History > 8 > currency
CNY
Earnings History > 8 > eps Actual
-0.2964
Earnings History > 8 > eps Estimate
0
Earnings History > 8 > eps Difference
-0.2964
Earnings History > 8 > surprise Percent
-
Earnings History > 9 > period
2019-03-31
Earnings History > 9 > report Date
2019-06-30
Earnings History > 9 > date
2019-03-31
Earnings History > 9 > before After Market
-
Earnings History > 9 > currency
CNY
Earnings History > 9 > eps Actual
-0.4009
Earnings History > 9 > eps Estimate
0
Earnings History > 9 > eps Difference
-0.4009
Earnings History > 9 > surprise Percent
-
Earnings History > 10 > period
2018-12-31
Earnings History > 10 > report Date
2019-03-31
Earnings History > 10 > date
2018-12-31
Earnings History > 10 > before After Market
-
Earnings History > 10 > currency
CNY
Earnings History > 10 > eps Actual
-0.4102
Earnings History > 10 > eps Estimate
0
Earnings History > 10 > eps Difference
-0.4102
Earnings History > 10 > surprise Percent
-
JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacture, and marketing of cellular immunotherapy products in the People's Republic of China. The company offers cell-based immunotherapies, including CAR-T treatment, a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an autologous anti-CD19 chimeric antigen receptor T-cell (CAR-T) immunotherapy for use in the treatment of a range of hematological cancers, as well as systemic lupus erythematosus (SLE), a chronic autoimmune disease. The company's products pipeline includes JWCAR129, a chimeric antigen receptor (CAR) construct therapy for use in the treatment of multiple myeloma; and JWCAR201, a dual targeting autologous CAR T-cell therapy for use in the treatment of B-cell malignancies and autoimmune diseases. It is also developing JWATM204 and JWATM214 for treating hepatocellular carcinoma (HCC); JWATM203 for the treatment of hepatoblastoma (HB) and hepatocellular carcinoma (HCC) in pediatric patients; JWATM213 for treating HCC; JWTCR001 for the treatment of various solid tumors; and JWCAR031 for the treatment of small cell lung cancer. In addition, the company engages in the drug research and development; medical research and experimental development; import and export handling; and clinical trial and CRO, as well as investment holding activities. JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, China.
Stock Price
$0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/A(Last Updated 2025-06-30)
Health Score
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Debt to Equity
-
High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of JW (Cayman) Therapeutics Co. Ltd
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
2025-12-31
EPS Estimate
—
Date
2021-03-31
EPS Actual
-0.055
EPS Estimate
0
EPS Difference
-0.055
Surprise Percent
0%
(Last Updated 2025-06-30)
(Last Updated 2025-06-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-06-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-06-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.